These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

229 related items for PubMed ID: 1355375

  • 1. Growth inhibition of estrogen independent MXT mouse mammary carcinomas in mice treated with an agonist or antagonist of LH-RH, an analog of somatostatin, or a combination.
    Szepeshazi K, Milovanovic S, Lapis K, Groot K, Schally AV.
    Breast Cancer Res Treat; 1992; 21(3):181-92. PubMed ID: 1355375
    [Abstract] [Full Text] [Related]

  • 2. Somatostatin analogs as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.
    Schally AV, Redding TW.
    Proc Natl Acad Sci U S A; 1987 Oct; 84(20):7275-9. PubMed ID: 2890164
    [Abstract] [Full Text] [Related]

  • 3. Receptors for D-Trp6-luteinizing hormone-releasing hormone, somatostatin, and insulin-like growth factor I in MXT mouse mammary carcinoma.
    Srkalovic G, Szende B, Redding TW, Groot K, Schally AV.
    Proc Soc Exp Biol Med; 1989 Dec; 192(3):209-18. PubMed ID: 2574866
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of growth of PC-82 human prostate cancer line xenografts in nude mice by bombesin antagonist RC-3095 or combination of agonist [D-Trp6]-luteinizing hormone-releasing hormone and somatostatin analog RC-160.
    Milovanovic SR, Radulovic S, Groot K, Schally AV.
    Prostate; 1992 Dec; 20(4):269-80. PubMed ID: 1376910
    [Abstract] [Full Text] [Related]

  • 5. Somatostatin analogue RC-160 and LH-RH antagonist SB-75 inhibit growth of MIA PaCa-2 human pancreatic cancer xenografts in nude mice.
    Radulovic S, Comaru-Schally AM, Milovanovic S, Schally AV.
    Pancreas; 1993 Jan; 8(1):88-97. PubMed ID: 8093555
    [Abstract] [Full Text] [Related]

  • 6. Inhibitory effects of analogs of luteinizing hormone-releasing hormone and somatostatin on pancreatic cancers in hamsters. Events that accompany tumor regression.
    Szende B, Srkalovic G, Schally AV, Lapis K, Groot K.
    Cancer; 1990 May 15; 65(10):2279-90. PubMed ID: 1971771
    [Abstract] [Full Text] [Related]

  • 7. Growth inhibition of mouse MXT mammary tumor by the luteinizing hormone-releasing hormone antagonist SB-75.
    Szende B, Srkalovic G, Groot K, Lapis K, Schally AV.
    J Natl Cancer Inst; 1990 Mar 21; 82(6):513-7. PubMed ID: 2156080
    [Abstract] [Full Text] [Related]

  • 8. Growth inhibition of MXT mammary carcinoma by enhancing programmed cell death (apoptosis) with analogs of LH-RH and somatostatin.
    Szende B, Lapis K, Redding TW, Srkalovic G, Schally AV.
    Breast Cancer Res Treat; 1989 Dec 21; 14(3):307-14. PubMed ID: 2575407
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of binding of cytotoxic analogs of luteinizing hormone-releasing hormone to human breast cancer and mouse MXT mammary tumor.
    Milovanovic SR, Radulovic S, Schally AV.
    Breast Cancer Res Treat; 1992 Dec 21; 24(2):147-58. PubMed ID: 8443402
    [Abstract] [Full Text] [Related]

  • 10. Effect of combination treatment with analogs of luteinizing hormone-releasing hormone (LH-RH) or somatostatin and 5-fluorouracil on pancreatic cancer in hamsters.
    Szepeshazi K, Lapis K, Schally AV.
    Int J Cancer; 1991 Sep 09; 49(2):260-6. PubMed ID: 1679045
    [Abstract] [Full Text] [Related]

  • 11. Programmed cell death (apoptosis) in pancreatic cancers of hamsters after treatment with analogs of both luteinizing hormone-releasing hormone and somatostatin.
    Szende B, Zalatnai A, Schally AV.
    Proc Natl Acad Sci U S A; 1989 Mar 09; 86(5):1643-7. PubMed ID: 2564204
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of mammary tumor growth in rats and mice by administration of agonistic and antagonistic analogs of luteinizing hormone-releasing hormone.
    Redding TW, Schally AV.
    Proc Natl Acad Sci U S A; 1983 Mar 09; 80(5):1459-62. PubMed ID: 6219395
    [Abstract] [Full Text] [Related]

  • 13. Presence of membrane binding sites for [D-TRP6]-luteinizing hormone-releasing hormone in experimental pancreatic cancer.
    Fekete M, Zalatnai A, Schally AV.
    Cancer Lett; 1989 May 09; 45(2):87-91. PubMed ID: 2567204
    [Abstract] [Full Text] [Related]

  • 14. Antitumor effects of analogs of LH-RH and somatostatin: experimental and clinical studies.
    Schally AV, Srkalovic G, Szende B, Redding TW, Janaky T, Juhasz A, Korkut E, Cai RZ, Szepeshazi K, Radulovic S.
    J Steroid Biochem Mol Biol; 1990 Dec 20; 37(6):1061-7. PubMed ID: 1981009
    [Abstract] [Full Text] [Related]

  • 15. Receptors for prolactin, somatostatin, and luteinizing hormone-releasing hormone in experimental prostate cancer after treatment with analogs of luteinizing hormone-releasing hormone and somatostatin.
    Kadar T, Redding TW, Ben-David M, Schally AV.
    Proc Natl Acad Sci U S A; 1988 Feb 20; 85(3):890-4. PubMed ID: 2893378
    [Abstract] [Full Text] [Related]

  • 16. Effect of luteinizing hormone-releasing hormone analogs containing cytotoxic radicals on growth of estrogen-independent MXT mouse mammary carcinoma in vivo.
    Szepeshazi K, Schally AV, Juhasz A, Nagy A, Janaky T.
    Anticancer Drugs; 1992 Apr 20; 3(2):109-16. PubMed ID: 1388062
    [Abstract] [Full Text] [Related]

  • 17. Effect of a cytotoxic analog of LH-RH (T-98) on the growth of estrogen-dependent MXT mouse mammary cancers: correlations between growth characteristics and EGF receptor content of tumors.
    Szepeshazi K, Schally AV, Halmos G, Szoke B, Groot K, Nagy A.
    Breast Cancer Res Treat; 1996 Apr 20; 40(2):129-39. PubMed ID: 8879679
    [Abstract] [Full Text] [Related]

  • 18. Combination of a long-acting delivery system for luteinizing hormone-releasing hormone agonist with Novantrone chemotherapy: increased efficacy in the rat prostate cancer model.
    Schally AV, Kook AI, Monje E, Redding TW, Paz-Bouza JI.
    Proc Natl Acad Sci U S A; 1986 Nov 20; 83(22):8764-8. PubMed ID: 2946045
    [Abstract] [Full Text] [Related]

  • 19. Sustained release formulations of luteinizing hormone-releasing hormone antagonist SB-75 inhibit proliferation and enhance apoptotic cell death of human prostate carcinoma (PC-82) in male nude mice.
    Redding TW, Schally AV, Radulovic S, Milovanovic S, Szepeshazi K, Isaacs JT.
    Cancer Res; 1992 May 01; 52(9):2538-44. PubMed ID: 1568223
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of growth of MCF-7 MIII human breast carcinoma in nude mice by treatment with agonists or antagonists of LH-RH.
    Yano T, Korkut E, Pinski J, Szepeshazi K, Milovanovic S, Groot K, Clarke R, Comaru-Schally AM, Schally AV.
    Breast Cancer Res Treat; 1992 May 01; 21(1):35-45. PubMed ID: 1391973
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.